Trichomonas Vaginalis Recurrence Among HIV+ Women

Randomized Phase IV Trial of Metronidazole Single Dose Versus 7 Day Dose for Treatment of Trichomonas Vaginalis Among HIV-infected Women

The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.

This is a Phase IV equivalency trial as both doses of metronidazole are listed in the the Centers for Disease Control and Prevention Treatment Guidelines for the treatment of T vaginalis.

Inclusion Criteria:

• Female
• 18 years or older
• HIV-positive
• TV positive by either wet preparation or culture
• ability to refrain from all alcohol use for 24 hours before and after taking oral metronidazole
• willing to take metronidazole treatment

Exclusion Criteria:

• pregnant
• incarcerated
• previously enrolled
• currently taking disulfiram
• alcoholism or known liver damage
• medical contraindications to metronidazole
• treated with metronidazole within the previous 14 days
• requires treatment for B.V. per Amsel's criteria